Craig Brown, Senior Vice President, Braeburn Pharmaceuticals, is an accomplished senior executive with over 20 years in key leadership positions within major pharmaceutical companies. In his role at Braeburn, he leading the development, commercialization and marketing of the innovative pipeline of Braeburn products. Braeburn’s first product, Propbuphine®, was approved by the FDA in May 2016. He has extensive industry experience including Global, U.S. marketing and Early Development; portfolio prioritization; protocol development; global alliance management and business development. Prior to joining Braeburn, Mr. Brown spent nine years at Otsuka Pharmaceuticals, Inc. where he oversaw the early development of the Global CNS pipeline and the global management of the CNS franchise. He was instrumental in launching ABILIFY®, which has achieved over 6 billion dollars in annual sales, and in the development of ABILIFY MAINTENA® and Rexulti. He was also responsible for the development of five investigational compounds (discovery through Phase IV), and played an integral role in the development process of CNS assets. He graduated from Georgia State University with a Bachelors Business Administration, Management.
Dying to Get High—Tackling the Opioid Epidemic